Isomorphic Labs, one of the leading AI-driven drug discovery companies within Alphabet, has reeled in $600 million in external financing as it nears the clinic.

FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop. Moderna down 11%, Sarepta down 7.5%, uniQure down 20%.

Studies that touch on LGBT+ health, gender identity and DEI in the biomedical workforce could be terminated, according to documents obtained by Nature.

The life science investment firm Bioluminescence Ventures will close its doors less than two years after its founding, despite raising nearly half a billion dollars to put into new companies, Endpoint...

PEPFAR’s computer systems also are being taken offline, a sign that the program may not return, as Republican critics had hoped.

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long slid...

Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, will step down, the agency confirmed Friday. An email was sent to employees announcing the departure.

AbbVie is taking a major loss in the wake of its Cerevel buyout. AbbVie said it will write off $3.5 billion following two mid-stage failures for emraclidine,

Four biotechs launch with $800M total: Windward Bio, Kardigan, Ouro Medicines & Timberlyne Therapeutics. Three licensed drugs from Chinese firms, while Kardigan has undisclosed cardio assets.

The Sunset Fire in the Hollywood Hills follows other blazes in the L.A. area, including the Palisades and Eaton fires, that have displaced tens of thousands.

HIV is now "Lentivirus humimdef1" by another name. Virus researchers are not happy.

There's a shopping bonanza for new obesity medicines going on among a marquee cohort of biopharma investors who are in-licensing treatment candidates from Chinese and European drug developers. Joining...

Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a neuroscience spinoff and running into a dealmaking hurdle with the FTC.

Regeneron, maker of the blockbuster ophthalmology medicine Eylea, has acquired an ocular biotech, the large biopharma confirmed to Endpoints News on Thursday.

2024 was the year of the private megaround. Nine-figure financings dominated biotech's venture funding landscape, with 96 such rounds tallied by Endpoints News. The bevy of megarounds drowned out smal...

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials for its experimental major depression drug, saying Thursday that navacaprant...

Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday, at the fag end of what has been a red-hot year for companies listing on the stock market.

A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been approved in a subcutaneous form that's becoming a new area of competition for ...

Novo Nordisk's CagriSema achieves 22.7% weight loss in Phase 3 trial, missing 25% target. Stock drops 26% as results fall short of expectations.

The FDA has reaffirmed that the shortage of Eli Lilly’s blockbuster obesity and diabetes medications is resolved, dealing a blow to pharmacies and telehealth services that have capitalized on providin...

Endpoints News reviews 2024's biopharma winners & losers: Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.

David Epstein has retired three times. And he quickly went to work when he got back in the saddle earlier this fall as CEO and chair of Ottimo Pharma, a ...

Ring Therapeutics, a startup looking to advance a new type of virus to deliver gene therapies, has let go

BioAge Labs, which began nearly a decade ago as an anti-aging biotech and then turned to obesity this year, is going back to its roots and teaming up with Novartis ...

Over the years, a handful of cities have tried catching up to the flourishing biotech hubs in Boston or the San Francisco Bay Area. Chicago, the third-largest city in the US, is putting together its b...

Former Padlock shareholders sue Bristol Myers Squibb over alleged unpaid milestone payments for antibody BMS-986454, claiming pharma giant failed to disclose clinical milestone achievement.

LONDON — Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on AI’s future in drug discovery. But he’s also grown exasperated at ...

The decision to lay off STAT employees comes after years of growth, including a significant expansion during the height of the COVID-19 pandemic.

The biotech and life sciences team at a16z is getting a new leader, as founding investor Vijay Pande moves into a role focused on artificial intelligence and its healthcare applications, Endpoints New...

BioAge Labs is scrapping a Phase 2 trial testing its anti-obesity drug, a few months after its flashy $198 million initial public offering. The California biotech said after the markets closed on Frid...

Despite months of biopharma industry pushback, the European Commission has unconditionally approved Novo Holdings’ $16.5 billion acquisition of Catalent. The Federal Trade Commission’s decision is exp...

San Francisco Hotel Workers are On Strike! Cancel the 2025 J.P. Morgan Healthcare Conference in San Francisco! The J.P. Morgan Healthcare Conference takes place annually in San Francisco and had 10,00...

A four-minute drive north of the Illinois-Wisconsin border in 'America's Dairyland,' Eli Lilly is staking one of its largest-ever manufacturing bets to continue its dominance in obesity drugs and supp...

UnitedHealthcare CEO Brian Thompson was shot and killed in Midtown Manhattan on Wednesday morning, according to media reports.

At a time when geopolitical tensions are hitting industries from semiconductors to electric vehicles, pharmaceutical dealmaking has become a rare bright spot for collaboration between China and the We...

Robert F. Kennedy Jr., Donald Trump’s pick for Health and Human Services secretary, also argued for jailing vaccine scientists in previously unreported comments at autism conferences.

The FDA said Wednesday that it is investigating

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of biobucks in recent years.

Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the FDA, according to a source familiar with the company. After